<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305862</url>
  </required_header>
  <id_info>
    <org_study_id>AMARIROCAP</org_study_id>
    <nct_id>NCT02305862</nct_id>
  </id_info>
  <brief_title>A High-Resolution Magnetic Resonance Imaging Study to Evaluate the Effect of Rosuvastatin on Carotid Atherosclerotic Plaques</brief_title>
  <official_title>An Open-label, Single-centre Randomized Study Evaluating the Effect of Treatment With Rosuvastatin 5/20mg on Atherosclerotic Disease as Measured by High-Resolution Contrast Enhanced Magnetic Resonance Imaging in Patients With Coronary Artery Disease and Hyperlipideimia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess whether high intensive statin therapy could regress
      carotid atherosclerotic plaques as determined by High-Resolution Contrast Enhanced Magnetic
      Resonance imaging (CE-MRI).

      Enrolled patients have a baseline CE-MRI examination for screening carotid atherosclerotic
      plaques and are randomized to either low dose of Rosuvastatin (5mg) group or high dose of
      Rosuvastatin (20mg) group. After 26 weeks, all patients received CE-MRI examination again and
      each pair of baseline and follow-up CE-MRI assessments was analyzed in a blinded fashion.
      Moreover, lipid level and major adverse cardiovascular events are also evaluated during
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate whether 26 weeks of treatment with 5/20mg rosuvastatin results in regression of carotid atherosclerotic plaques as measured by CE-MRI</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiovascular events</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change in lipid and lipoprotein levels as assessed by percentage change from baseline.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change from baseline in liver function (AST/ALT) at 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change from baseline in renal function (serum creatine) at 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change from baseline in creatine kinase at 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Arteriosclerosis</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Lipid Disorder</condition>
  <arm_group>
    <arm_group_label>low dose group (5mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose group (20mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose Rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 5mg</intervention_name>
    <description>drug intervention</description>
    <arm_group_label>low dose group (5mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <description>drug intervention</description>
    <arm_group_label>high dose group (20mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients with coronary artery disease or carotid atherosclerotic plaque or hyperlipideimia
        or old myocardial infarction

        Exclusion Criteria:

          -  Planning coronary stenting

          -  Heart failure

          -  Uncontrolled hypertension（≥200/110mmHg)

          -  Uncontrolled diabetes mellitus (HbA1C≥9.5%)

          -  Hepatic insufficiency

          -  Renal dysfunction

          -  Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Buxing Chen, MD, Ph.D</last_name>
    <phone>861067096572</phone>
    <email>chbux@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Fu, Dr</last_name>
      <phone>861067096562</phone>
      <email>fuqiang66882000@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Buxing Chen, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Buxing Chen</investigator_full_name>
    <investigator_title>Director of department of cardiology</investigator_title>
  </responsible_party>
  <keyword>Coronary Arteriosclerosis</keyword>
  <keyword>Carotid Atherosclerotic Plaque</keyword>
  <keyword>Rosuvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

